SE0104340D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE0104340D0
SE0104340D0 SE0104340A SE0104340A SE0104340D0 SE 0104340 D0 SE0104340 D0 SE 0104340D0 SE 0104340 A SE0104340 A SE 0104340A SE 0104340 A SE0104340 A SE 0104340A SE 0104340 D0 SE0104340 D0 SE 0104340D0
Authority
SE
Sweden
Prior art keywords
sup
new compounds
active compounds
new
compounds
Prior art date
Application number
SE0104340A
Other languages
English (en)
Swedish (sv)
Inventor
Stefan Berg
Ratan Bhat
James Empfield
Sven Hellberg
Mike Klimas
James Woods
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0104340A priority Critical patent/SE0104340D0/xx
Publication of SE0104340D0 publication Critical patent/SE0104340D0/xx
Priority to PCT/SE2002/002373 priority patent/WO2003053330A2/en
Priority to AU2002359164A priority patent/AU2002359164A1/en
Priority to AT02793678T priority patent/ATE361287T1/de
Priority to ES02793678T priority patent/ES2284964T3/es
Priority to US10/499,217 priority patent/US7205314B2/en
Priority to EP02793678A priority patent/EP1458707B1/de
Priority to DE60219954T priority patent/DE60219954T2/de
Priority to JP2003554090A priority patent/JP4465188B2/ja
Priority to JP2009201189A priority patent/JP2009280618A/ja

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SE0104340A 2001-12-20 2001-12-20 New compounds SE0104340D0 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE0104340A SE0104340D0 (sv) 2001-12-20 2001-12-20 New compounds
PCT/SE2002/002373 WO2003053330A2 (en) 2001-12-20 2002-12-18 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer’s disease and conditions associated with glycogen synthase kinase-3
AU2002359164A AU2002359164A1 (en) 2001-12-20 2002-12-18 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
AT02793678T ATE361287T1 (de) 2001-12-20 2002-12-18 Neue indol-2-on derivate
ES02793678T ES2284964T3 (es) 2001-12-20 2002-12-18 Nuevos derivados de indol-2-ona.
US10/499,217 US7205314B2 (en) 2001-12-20 2002-12-18 Compounds for the treatment of dementia related diseases
EP02793678A EP1458707B1 (de) 2001-12-20 2002-12-18 Neue Indol-2-on Derivate
DE60219954T DE60219954T2 (de) 2001-12-20 2002-12-18 Neue Indol-2-on Derivate
JP2003554090A JP4465188B2 (ja) 2001-12-20 2002-12-18 新規な化合物
JP2009201189A JP2009280618A (ja) 2001-12-20 2009-09-01 新規な化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0104340A SE0104340D0 (sv) 2001-12-20 2001-12-20 New compounds

Publications (1)

Publication Number Publication Date
SE0104340D0 true SE0104340D0 (sv) 2001-12-20

Family

ID=20286439

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0104340A SE0104340D0 (sv) 2001-12-20 2001-12-20 New compounds

Country Status (9)

Country Link
US (1) US7205314B2 (de)
EP (1) EP1458707B1 (de)
JP (2) JP4465188B2 (de)
AT (1) ATE361287T1 (de)
AU (1) AU2002359164A1 (de)
DE (1) DE60219954T2 (de)
ES (1) ES2284964T3 (de)
SE (1) SE0104340D0 (de)
WO (1) WO2003053330A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1458711B1 (de) 2001-12-21 2007-07-18 AstraZeneca AB Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
SE0302546D0 (sv) * 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
JP5069907B2 (ja) 2003-09-17 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 縮合複素環式化合物
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007000240A1 (en) 2005-06-28 2007-01-04 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
BRPI0614063A2 (pt) 2005-07-26 2011-03-09 Sanofi Aventis derivados de cicloexilamina isoquinolona
AU2006274245B2 (en) 2005-07-26 2011-11-24 Sanofi-Aventis Piperidinyl-substituted isoquinolone derivatives as Rho-kinase inhibitors
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
DK1942898T4 (da) 2005-09-14 2014-06-02 Takeda Pharmaceutical Dipeptidylpeptidase-inhibitorer til behandling af diabetes
KR101368988B1 (ko) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1991531A1 (de) * 2006-02-28 2008-11-19 Amgen Inc. Cinnolin- und chinoxalinderivate als phosphodiesterase-10-hemmer
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7851468B2 (en) * 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
JP5406030B2 (ja) 2006-10-21 2014-02-05 アボット ゲーエムベーハー ウント カンパニー カーゲー 複素環化合物およびそれらのグリコーゲンシンターゼキナーゼ3阻害薬としての使用
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AU2007338408B2 (en) 2006-12-27 2012-07-26 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
CA2673920C (en) 2006-12-27 2015-03-24 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
MX2009005828A (es) 2006-12-27 2009-06-16 Sanofi Aventis Derivados de isoquinolona e isoquinolinona sustituidos con cicloalquilamina.
EP2125745B1 (de) 2006-12-27 2017-02-22 Sanofi Cycloalkylaminsubstituierte isochinolonderivate
JP5318779B2 (ja) 2006-12-27 2013-10-16 サノフイ シクロアルキルアミン置換イソキノリン及びイソキノリノン誘導体
NZ577981A (en) 2006-12-27 2011-12-22 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
BRPI0720909A2 (pt) 2006-12-27 2016-11-01 Sanofi Aventis derivados de isoquinolina e isoquinolinona substituídos
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US20090291982A1 (en) * 2008-05-22 2009-11-26 Astrazeneca Ab New Substituted Oxindole Derivative 352
KR101607090B1 (ko) 2008-06-24 2016-03-29 사노피 6-치환된 이소퀴놀린 및 이소퀴놀리논
US8524737B2 (en) 2008-06-24 2013-09-03 Sanofi Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives
ES2541827T3 (es) 2008-06-24 2015-07-27 Sanofi Isoquinolinas e isoquinolinonas sustituidas como inhibidores de Rho-cinasa
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP2621914B1 (de) 2010-09-27 2016-12-28 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als glycogensynthasekinase-3-inhibitoren
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2023097151A1 (en) * 2021-11-29 2023-06-01 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
EP1105376B1 (de) 1998-08-20 2005-02-09 Sumitomo Pharmaceuticals Company, Limited Wachstumshormon-freisetzende oxindolderivate
EP1136493A1 (de) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Thienopyridinyl)pyrimidon-, 2-(Furopyridinyl)pyrimidon-2-(isoquinolinyl)pyrimidon-, 2-(Pyridoindolyl)pyrimidon- und 2-(Benzofuropyridinyl)pyrimidonderivate

Also Published As

Publication number Publication date
US20050065170A1 (en) 2005-03-24
US7205314B2 (en) 2007-04-17
EP1458707A2 (de) 2004-09-22
DE60219954T2 (de) 2008-01-17
WO2003053330A2 (en) 2003-07-03
EP1458707B1 (de) 2007-05-02
AU2002359164A1 (en) 2003-07-09
WO2003053330A3 (en) 2003-10-30
ATE361287T1 (de) 2007-05-15
JP2005513082A (ja) 2005-05-12
JP2009280618A (ja) 2009-12-03
ES2284964T3 (es) 2007-11-16
AU2002359164A8 (en) 2003-07-09
JP4465188B2 (ja) 2010-05-19
DE60219954D1 (de) 2007-06-14

Similar Documents

Publication Publication Date Title
SE0104340D0 (sv) New compounds
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
EP1562897A4 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
SE0102439D0 (sv) New compounds
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
HUP0401192A2 (hu) Fényérzékenyítő szer alkalmazása sebek kezelésére adható gyógyászati készítmény előállítására
DE60226729D1 (de) Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
SE0102438D0 (sv) New compounds
SE9902987D0 (sv) Novel compounds
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
UY27592A1 (es) Nuevo uso
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
SE0104334D0 (sv) Therapeutic agents
TW200745111A (en) New compounds
SE0104341D0 (sv) New use
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
EP1689713A4 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
GEP20053459B (en) New Thiadiazoles and Oxidiazoles and Their Use as Phosphodiesterase-7 Inhibitors
SE0100569D0 (sv) New compounds
SE0104331D0 (sv) Novel compounds
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
SE9902765D0 (sv) Novel compounds